Andrea R Genazzani
Overview
Explore the profile of Andrea R Genazzani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
120
Citations
1357
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benagiano G, Genazzani A, Grandi G, Guo S, Habiba M
PLoS Comput Biol
. 2024 Dec;
20(12):e1012398.
PMID: 39693279
The optimal contraception dosing strategy proposed by Gavina et al. recently is a commendable attempt to model a complex physiological process with potenial to apply to real-life data. However, there...
2.
Fidecicchi T, Giannini A, Chedraui P, Luisi S, Battipaglia C, Genazzani A, et al.
Maturitas
. 2024 Aug;
188:108087.
PMID: 39111089
The menopause transition is an important period in a woman's life, during which she is at an increased risk of mood disorders. Estrogen and progesterone fluctuations during the menopausal transition...
3.
Genazzani A, Divakar H, Khadilkar S, Monteleone P, Evangelisti B, Galal A, et al.
Int J Gynaecol Obstet
. 2024 Jan;
164(2):516-530.
PMID: 38178609
Menopause marks the end of menstrual cyclicity and, depending on individual vulnerability, has several consequences related to gonadal steroid deprivation, especially if it is premature. Menopause may be more burdensome...
4.
Genazzani A, Fidecicchi T, Arduini D, Giannini A, Simoncini T
Gynecol Endocrinol
. 2023 Aug;
39(1):2247093.
PMID: 37599373
The debate about contraception has become increasingly important as more and more people seek safe and effective contraception. More than 1 billion women of reproductive age worldwide need a method...
5.
Genazzani A, Genazzani A
touchREV Endocrinol
. 2023 Jun;
19(1):71-77.
PMID: 37313240
Polycystic ovary syndrome (PCOS) is a very frequent disease that affects reproductive ability and menstrual regularity. Other than the criteria established at the Rotterdam consensus, in these last few years...
6.
Antonelli A, Giannini A, Chedraui P, Monteleone P, Caretto M, Genazzani A, et al.
Gynecol Endocrinol
. 2022 Nov;
38(12):1019-1027.
PMID: 36433781
Depressive disorders and anxiety states represent one of the most frequent psychiatric pathologies occurring transiently in vulnerable women throughout their life, from puberty to menopause. It is now known that...
7.
Mendoza N, Ramirez I, de la Viuda E, Coronado P, Baquedano L, Llaneza P, et al.
Maturitas
. 2022 Sep;
166:65-85.
PMID: 36081216
This project aims to develop eligibility criteria for menopausal hormone therapy (MHT). The tool should be similar to those already established for contraception A consortium of scientific societies coordinated by...
8.
Petrillo T, Semprini E, Tomatis V, Arnesano M, Ambrosetti F, Battipaglia C, et al.
Biomedicines
. 2022 Aug;
10(8).
PMID: 36009471
Polycystic ovary syndrome (PCOS) is the most frequent endocrine-metabolic disorder among women at reproductive age. The diagnosis is based on the presence of at least two out of three criteria...
9.
Petrillo T, Battipaglia C, Virmani M, Genazzani A, Genazzani A
Int J Mol Sci
. 2021 Oct;
22(19).
PMID: 34639120
Carnitines are quaternary amines involved in various cellular processes such as fatty acid uptake, β-oxidation and glucose metabolism regulation. Due to their neurotrophic activities, their integrative use has been studied...
10.
Genazzani A, Monteleone P, Giannini A, Simoncini T
Hum Reprod Update
. 2021 Aug;
27(6):1115-1150.
PMID: 34432008
Background: Menopausal symptoms can be very distressing and considerably affect a woman's personal and social life. It is becoming more and more evident that leaving bothersome symptoms untreated in midlife...